Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

PNGS Reva Diamond IPO Review: APPLY or AVOID? | What You Need to Know

By Jagat Joshi
February 23, 2026

PNGS Reva Diamond IPO is one of the most-awaited IPOs of 2026 and is finally launching. PNGS Reva Diamond is one of the leading jewellery brands that makes a wide range of jewellery products crafted with diamonds, precious, and semi-precious stones, and metals like gold and platinum.

The IPO will be open for subscription on February 24, 2026, and close on February 26, 2026. The PNGS Reva Diamond IPO price band is set between ₹367 to ₹386 per share, with a face value of ₹10 each. As per the RHP, the company plans to raise around ₹380 crores through an Initial Public Offering

Review IPO Details GMP Messages Subscription Allotment Listing

As an investor, it can be very challenging to decide whether the PNGS Reva Diamond IPO is a good or bad investment. Not anymore. On this blog, we will provide you with all the necessary details related to the PNGS Reva Diamond IPO to help you decide whether to apply or not. Read on to know the IPO risks, strengths, valuation, financial details, and expert opinion to make your investment decision better.

Strengths:

PNGS Reva Diamond operates 34 stores divided into 3 types: FOCO, FOFO, and COCO, making the expansion flexible.
The brand Reva Diamond is growing on legacy, industry knowledge, relationships with promoters, and customer trust.

The firm has a strong regional presence across Tier-1, Tier-2, and Tier-3 cities.

A diversified range of high-quality products in the portfolio includes Rings, bracelets, bangles, Chains, Nose pins, Pendants, Earrings, Mangalsutras, Necklaces, etc, at different price points.

The IPO is a fresh issue, meaning the funds will be used for the company’s expansion and growth.

Weaknesses:

The 97% of the firm’s revenue comes from the stores in Maharashtra, meaning if any issue occurs in this region, it can disrupt the company’s financials, performance, and financial health.

PNGS Reva Diamond’s brand reputation is dependent on Corporate Promoter, P. N. Gadgil & Sons Limited. If their brand image is damaged, it can adversely affect the business, reduce customer visits, and revenue.

Over natural diamonds or gemstones, Lab-grown and synthetic diamonds are receiving more popularity due to their low cost and accessibility. If not able to compete with the prices of synthetic diamonds, can impact the company’s sales and revenue.

Failing to market its products correctly will reduce the customers’ visits to stores, which can negatively affect the business, cash flow, and financial condition.

PNGS Reva Diamond IPO Review

Reviewer	Reccomendation
IPO Watch	May Apply
Adroit Financial Services	Apply
Lakshmishree Investment & Securities	Apply
Axis Capital	Not Rated
Marwadi Shares and Finance	Apply
SBICAP Securities	Not Rated

Peer Comparison with the Company

Name of the Company	Face Value(₹)	Basic EPS (₹)	Diluted EPS	RONW (%)	P/E Ratio	NAV(₹)
PNGS Reva Diamond	10	35.21	35.21	59.36%	10.96	45.82
Peer Groups
Tribhovandas Bhimji Zaveri Limited	10	10.25	10.25	10.41%	15.74	98.49
Thangamayil Jewellery Limited	10	42.00	42.00	10.77%	80.96	390.03
Senco Gold Limited	10	10.09	10.08	8.09%	33.00	120.37

Industry peer group P/E ratio

In the retail jewellery industry, the P/E ratio ranges from a low of 15.74 to a high of 80.96, with an average of 43.23.

Promoters & Track Records, if any

Govind Vishwanath Gadgil, aged 66 years, is the Chairman, Non-Executive Director, and the Promoter of the Company. He holds 6,975,000 Equity shares, representing 31.90% of the pre-issue equity share capital.

Renu Govind Gadgil, aged 64 years, is the Promoter of the Company. She holds 6,975,000 Equity shares, representing 31.90% of the pre-issue equity share capital.

P. N. Gadgil & Sons Limited is the corporate promoter of PNGS Reva Diamond Jewellery. It holds 4,207,500 equity shares, representing 19.24% of the pre-issue equity share capital.

Expansion

Out of the total, the fund of ₹286.56 from the fresh issue will be utilized to set up 15 new stores.

The fund of ₹35.40 crore will be used towards the Marketing and promotional expenses of launching 15 new stores, to increase the brand awareness and make people more aware.

Lastly, the remaining funds will be used for the general corporate purposes.

PNGS Reva Diamond IPO – Should You Apply or Not?

Established jewellery brand, PNGS Reva Diamond, makes modern diamond, gold, and platinum jewellery designs, opening for subscription on 24th February. The firm operates its business with a trusted legacy of P. N. Gadgil & Sons (PNGS), which has more than 190 years in the gems and jewellery sector. The company is competing with some major brands like Titan, Kalyan, and regional jewellers. Financially, in FY25, the revenue from operations increased to ₹259.11 crores from ₹196.24 crores in FY24. After experiencing a decline in EBITDA and PAT in FY24, the firm made a strong comeback in FY25, reporting EBITDA of ₹79.61 crore and PAT of ₹59.47 crore. However, the Debt to Equity ratio has increased by 1.10 in the last 6 months of FY25.

The PNGS Reva Diamond P/E ratio is 10.96. After comparing to the industry peer group P/E, the company appears to be fairly valued. As of 23rd February, the PNGS Reva Diamond IPO GMP is ₹18, showcasing a listing gain of around 4-5%.

To sum up, the attractive valuations, promising growth plans, improving financial track record, and strong parentage of P.N. Gadgil indicate reasonable listing gains. However, some risks like high geographic concentration, volatility in gold and diamond prices, and dependence on only physical stores should not be avoided by investors.

If the overall market sentiment and GMP stay in support, then investors can subscribe for the IPO for short-term gains. While cautious investors must analyze the risks associated with companies, such as high debt levels and high inventory funding, before subscribing.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article is written using information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.